Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures
- 140 Downloads
We report a case of unusually long-lasting remission of type 1 diabetes (T1D). The patient, a Caucasian man, at the age of 43 years developed a ketotic diabetes, classified as type 1 based on clinical presentation and positivity for islet autoantibodies. Shortly after diabetes onset, oral topiramate was added to preexisting valproic acid for generalized seizures and maintained thereafter. Initial intensive insulin treatment was rapidly reduced to low doses (3 Units/day) maintained for a long time and then discontinued at month 55; fasting glucose and glycosylated hemoglobin were basically normalized at 58 months. An oral glucose tolerance test performed at month 53 showed an impaired fasting glucose (6.0 mmol/l) and a value slightly above the threshold for the diagnosis of diabetes at 2 h (11.2 mmol/l). We hypothesize that this unusually prolonged preservation of β-cell function might be ascribed to the concomitant therapy with topiramate, an antiepileptic agent with demonstrated efficacy as antidiabetic in type 2 diabetes (T2D). Topiramate should be further investigated as candidate agent for the preservation of β-cell function also in T1D.
KeywordsType 1 diabetes (T1D) Remission phase Topiramate
We thank L. Adorini for the critical review of the manuscript and advice.
Conflict of interest
All the Authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
- 2.Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E (1998) Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 15(10):844–850PubMedCrossRefGoogle Scholar
- 3.Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop. Diabetes 53:250–264PubMedCrossRefGoogle Scholar
- 4.DCCT Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 128:517–523Google Scholar
- 5.US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2008) Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention, draft guidance. http://www.fda.gov/cder/guidance/7630dft.pdf
- 6.Calcaterra V, Bottazzi A, Tzialla C, D’Arrigo S, Larizza D (2011) Iatrogenic diabetes mellitus during ACTH therapy in an infant with West syndrome. Acta Diabetol. doi: 10.1007/s00592-011-0253-5
- 8.Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M (2007) Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes 31(1):138–146CrossRefGoogle Scholar
- 10.Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A (2007) A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 30(6):1480–1486PubMedCrossRefGoogle Scholar
- 12.Rolandsson O, Palmer JP (2010) Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 53(7):1250–1253Google Scholar
- 13.Jin P, Huang G, Lin J, Luo S, Zhou Z (2011) Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol. doi: 10.1007/s00592-010-0250-0
- 15.Olson JA, Olson DM, Sandborg C, Alexander S, Buckingham B (2002) Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics 109(3):E50Google Scholar
- 26.Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, Saouaf SJ, Greene MI (2007) FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 104(11):4571–4576PubMedCrossRefGoogle Scholar
- 28.Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M (2010) ITN-JDRF Type 1 diabetes combination therapy assessment group. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160(2):176–184PubMedCrossRefGoogle Scholar